Archive · 1 Sep 2025
Wegovy Shows 57% Reduction in Heart Risk Compared to Competitor
Imagine two medicines for people who are overweight and have heart problems.
One medicine is called Wegovy, and the other is called Mounjaro/Zepbound.
A new study looked at how well these medicines help prevent heart attacks, strokes, and death.
The study found that Wegovy did a much better job, cutting the risk by a lot more than the other medicine.
In a group of people who took Wegovy, very few had a heart problem.
This shows that Wegovy might be a better choice to protect the heart.
The study involved many people who were at least 45 years old.
Novo Nordisk made the medicine Wegovy.
Eli Lilly makes the other medicine.
Novo Nordisk states Wegovy reduces heart attack, stroke, or death risk by 57% compared to Eli Lilly’s Mounjaro and Zepbound.
The study suggests the heart-protective benefits of semaglutide may differ from tirzepatide.
The real-world study examined data from actual patient experiences.
Study included overweight/obese patients with cardiovascular disease who did not have diabetes.
The study included evidence from over 21,000 patients aged at least 45.
- Who
- Novo Nordisk
- What
- Reported Wegovy reduces heart attack, stroke, or death risk by 57% compared to Eli Lilly's Mounjaro and Zepbound.
- When
- Data presented on Sunday
- Where
- European Society of Cardiology Congress in Madrid, Spain
- Why
- To highlight the heart-protective benefits of Wegovy for people living with obesity and cardiovascular disease.
- Drug
- Wegovy
- Active Ingredient (Wegovy)
- Semaglutide
- Active Ingredient (Mounjaro/Zepbound)
- Tirzepatide
- Risk Reduction
- 57% for major cardiovascular events with Wegovy vs. tirzepatide
- Study Participants
- Over 21,000 patients
- Age of Participants
- At least 45 years old